- Home
- CLDI vs GRFX Comparison
CLDI vs GRFX Comparison
Compare CLDI & GRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- GRFX
- Stock Information
- Founded
- CLDI 2014
- GRFX 1981
- Country
- CLDI United States
- GRFX Hong Kong
- Employees
- CLDI N/A
- GRFX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- GRFX
- Sector
- CLDI Health Care
- GRFX
- Exchange
- CLDI Nasdaq
- GRFX Nasdaq
- Market Cap
- CLDI 15.7M
- GRFX 18.1M
- IPO Year
- CLDI N/A
- GRFX N/A
- Fundamental
- Price
- CLDI $0.40
- GRFX $0.96
- Analyst Decision
- CLDI Strong Buy
- GRFX Hold
- Analyst Count
- CLDI 2
- GRFX 1
- Target Price
- CLDI $15.00
- GRFX N/A
- AVG Volume (30 Days)
- CLDI 202.0K
- GRFX 24.7K
- Earning Date
- CLDI 05-20-2025
- GRFX 01-01-0001
- Dividend Yield
- CLDI N/A
- GRFX 0.02%
- EPS Growth
- CLDI N/A
- GRFX N/A
- EPS
- CLDI N/A
- GRFX N/A
- Revenue
- CLDI N/A
- GRFX $24,184,100.00
- Revenue This Year
- CLDI N/A
- GRFX N/A
- Revenue Next Year
- CLDI N/A
- GRFX N/A
- P/E Ratio
- CLDI N/A
- GRFX N/A
- Revenue Growth
- CLDI N/A
- GRFX N/A
- 52 Week Low
- CLDI $0.35
- GRFX $0.71
- 52 Week High
- CLDI $4.90
- GRFX $2.75
- Technical
- Relative Strength Index (RSI)
- CLDI 36.62
- GRFX 50.10
- Support Level
- CLDI $0.40
- GRFX $0.75
- Resistance Level
- CLDI $0.46
- GRFX $1.04
- Average True Range (ATR)
- CLDI 0.04
- GRFX 0.11
- MACD
- CLDI 0.00
- GRFX 0.00
- Stochastic Oscillator
- CLDI 9.73
- GRFX 56.87
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.